Analysts Hold Invivyd Price Target Steady as FDA Progress and Valuation Metrics Update

AN

AnalystConsensusTarget

AnalystConsensusTarget

Not Invested

Based on Analyst Price Targets

Published

23 Apr 25

Updated

18 Dec 25

Views

385

n/a

n/a

AnalystConsensusTarget's Fair Value

n/a

1Y

432.9%

7D

-3.8%

Loading

1Y

432.9%

7D

-3.8%

You can edit this narrative until Dec 19 11:08 PM. Then, changes will post as Updates.

Author's Valuation

US$1077.1% undervalued

AnalystConsensusTarget Fair Value

Shared on 18 Dec 25

IVVD: REVOLUTION Program Launch Will Drive Future Regulatory And Commercial Upside

Analysts have raised their price target on Invivyd to $10 from $5, citing the launch of the REVOLUTION clinical program for VYD2311 as a meaningful inflection point that enhances the company’s regulatory and commercial outlook. Analyst Commentary Following the launch of the REVOLUTION clinical program for VYD2311, equity research has focused on how the new data and development path could reshape Invivyd's long term growth and valuation profile.

Shared on 04 Dec 25

Fair value Increased 36%

IVVD: REVOLUTION Program Launch Will Drive Future Regulatory And Commercial Upside

Analysts have raised their price target on Invivyd to $10 from $5, citing the launch of the REVOLUTION program for VYD2311 as a key inflection point that improves the company's regulatory and commercial outlook. Analyst Commentary Analysts interpreting the updated price target see the REVOLUTION program as a pivotal moment for Invivyd, shifting expectations for both execution and long term growth potential.

Shared on 20 Nov 25

IVVD: REVOLUTION Program Initiation Will Drive Regulatory Momentum and Commercial Outlook

Analysts have raised their price target for Invivyd from $5 to $10, citing the launch of the REVOLUTION clinical program as a pivotal development. This new program is expected to enhance the company's regulatory and commercial outlook.

Shared on 05 Nov 25

Fair value Increased 29%

IVVD: FDA Clearance and REVOLUTION Program Launch Signal Strong Upside Ahead

Narrative Update: Invivyd Analyst Price Target Increased Invivyd's analyst price target has been raised from $5.67 to $7.33 per share. Analysts cite strengthened commercial and regulatory prospects following the launch of the REVOLUTION clinical program.

Shared on 22 Oct 25

Narrative Update on Invivyd: Analyst Price Target Revision Analysts have maintained Invivyd's price target at $5.67, citing consistent profit margin expectations along with only minor adjustments to the discount rate and future earnings estimates. What's in the News The FDA has cleared Invivyd's Investigational New Drug application, advancing the REVOLUTION clinical program for VYD2311, a monoclonal antibody candidate for COVID-19 prevention (Product-Related Announcements).

Shared on 08 Oct 25

Fair value Increased 89%

Narrative Update on Invivyd Price Target Analysts have raised Invivyd’s price target from $3.00 to $5.67, citing updated forecasts and changes in market expectations. What's in the News The U.S. FDA cleared Invivyd’s Investigational New Drug application, enabling advancement of the REVOLUTION clinical program for VYD2311, a monoclonal antibody candidate for COVID-19 prevention (Key Developments).

Shared on 16 Aug 25

Fair value Decreased 39%

Invivyd’s fair value estimate has been sharply reduced, driven by lowered revenue growth projections and a decline in expected net profit margins, resulting in a consensus analyst price target drop from $4.93 to $2.93. What's in the News Invivyd’s monoclonal antibody pemivibart (PEMGARDA) has shown strong protection (84% relative risk reduction) against symptomatic COVID-19 in immunocompromised and at-risk populations in the placebo-controlled CANOPY Phase 3 trial, supporting its Emergency Use Authorization (EUA) for pre-exposure prophylaxis.

Shared on 01 May 25

Fair value Decreased 25%

AnalystConsensusTarget Fair Value

US$10

77.1% undervalued

Future estimation in

Growth p.a.

Growth p.a.

%

Decrease

Increase

Current revenue growth rate

47.78%

Biotech revenue growth rate

9.68%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

%

0

Decrease

Increase

Current discount rate

7.02%

Calculation

US$13.64m

Earnings '28

x

460.60x

PE Ratio '28

=

US$6.28b

Market Cap '28

US$6.28b

Market Cap '28

/

512.17m

No. shares '28

=

US$12.26

Share Price '28

US$12.26 Share Price '28

Discounted to 2025 @ 7.04% p.a.

=

US$10.00

Fair Value '25